Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: Population pharmacokinetics, absolute bioavailability, and treatment outcome

Mohammed Al Za'abi, Timothy Donovan, David Tudehope, Paul Woodgate, Li An Collie, Bruce Charles

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A population pharmacokinetic model was developed after administration of orogastric and/or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants. Plasma indomethacin concentrations (n = 227) were obtained from 90 preterm infants of median gestational age 27 weeks, mean postnatal age of 12 days, and a mean current weight (WT) of 1010 g. Infants received one to three courses of indomethacin (0.1 mg/kg per day for 6 days). A one-compartment model was fitted to the data to obtain estimates of clearance (CL), volume of distribution (V), absorption rate constant (Ka) and orogastric bioavailability (F), using NONMEM. Model robustness was assessed by bootstrapping with replacement (500 samples). The structural model was: CL (L/h) = 0.0166 (WT ÷ 0.936); V (L) = 0.484 (WT ÷ 0.936); F = 0.986; Ka (h) = 0.786. The interindividual variability for CL and V was 57.7% and 45.6%, respectively. There remained considerable residual unexplained variability (45.4%). Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively. Complete ductus closure occurred in 67% of patients. Infants of lower gestational age or birth weight had less chance of successful ductal closure. There was no obvious dose-response relationship between systemic exposure to varying plasma indomethacin concentrations and ductus closure, which does not support individualized indomethacin dosing based on monitoring to a target plasma concentration.

Original languageEnglish
Pages (from-to)807-814
Number of pages8
JournalTherapeutic Drug Monitoring
Volume29
Issue number6
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Patent Ductus Arteriosus
Pharmacokinetics
Indomethacin
Intravenous Administration
Biological Availability
Newborn Infant
Population
Plasmas
Weights and Measures
Premature Infants
Gestational Age
Structural Models
Birth Weight
Half-Life
Rate constants
Monitoring

Keywords

  • Ductus arteriosus
  • Indomethacin
  • Population pharmacokinetics
  • Preterm infants
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus : Population pharmacokinetics, absolute bioavailability, and treatment outcome. / Za'abi, Mohammed Al; Donovan, Timothy; Tudehope, David; Woodgate, Paul; Collie, Li An; Charles, Bruce.

In: Therapeutic Drug Monitoring, Vol. 29, No. 6, 12.2007, p. 807-814.

Research output: Contribution to journalArticle

@article{3d5e56b4f77a4d4aad8ce04de3c507c0,
title = "Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: Population pharmacokinetics, absolute bioavailability, and treatment outcome",
abstract = "A population pharmacokinetic model was developed after administration of orogastric and/or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants. Plasma indomethacin concentrations (n = 227) were obtained from 90 preterm infants of median gestational age 27 weeks, mean postnatal age of 12 days, and a mean current weight (WT) of 1010 g. Infants received one to three courses of indomethacin (0.1 mg/kg per day for 6 days). A one-compartment model was fitted to the data to obtain estimates of clearance (CL), volume of distribution (V), absorption rate constant (Ka) and orogastric bioavailability (F), using NONMEM. Model robustness was assessed by bootstrapping with replacement (500 samples). The structural model was: CL (L/h) = 0.0166 (WT ÷ 0.936); V (L) = 0.484 (WT ÷ 0.936); F = 0.986; Ka (h) = 0.786. The interindividual variability for CL and V was 57.7{\%} and 45.6{\%}, respectively. There remained considerable residual unexplained variability (45.4{\%}). Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively. Complete ductus closure occurred in 67{\%} of patients. Infants of lower gestational age or birth weight had less chance of successful ductal closure. There was no obvious dose-response relationship between systemic exposure to varying plasma indomethacin concentrations and ductus closure, which does not support individualized indomethacin dosing based on monitoring to a target plasma concentration.",
keywords = "Ductus arteriosus, Indomethacin, Population pharmacokinetics, Preterm infants, Therapeutic drug monitoring",
author = "Za'abi, {Mohammed Al} and Timothy Donovan and David Tudehope and Paul Woodgate and Collie, {Li An} and Bruce Charles",
year = "2007",
month = "12",
doi = "10.1097/FTD.0b013e31815b3e13",
language = "English",
volume = "29",
pages = "807--814",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus

T2 - Population pharmacokinetics, absolute bioavailability, and treatment outcome

AU - Za'abi, Mohammed Al

AU - Donovan, Timothy

AU - Tudehope, David

AU - Woodgate, Paul

AU - Collie, Li An

AU - Charles, Bruce

PY - 2007/12

Y1 - 2007/12

N2 - A population pharmacokinetic model was developed after administration of orogastric and/or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants. Plasma indomethacin concentrations (n = 227) were obtained from 90 preterm infants of median gestational age 27 weeks, mean postnatal age of 12 days, and a mean current weight (WT) of 1010 g. Infants received one to three courses of indomethacin (0.1 mg/kg per day for 6 days). A one-compartment model was fitted to the data to obtain estimates of clearance (CL), volume of distribution (V), absorption rate constant (Ka) and orogastric bioavailability (F), using NONMEM. Model robustness was assessed by bootstrapping with replacement (500 samples). The structural model was: CL (L/h) = 0.0166 (WT ÷ 0.936); V (L) = 0.484 (WT ÷ 0.936); F = 0.986; Ka (h) = 0.786. The interindividual variability for CL and V was 57.7% and 45.6%, respectively. There remained considerable residual unexplained variability (45.4%). Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively. Complete ductus closure occurred in 67% of patients. Infants of lower gestational age or birth weight had less chance of successful ductal closure. There was no obvious dose-response relationship between systemic exposure to varying plasma indomethacin concentrations and ductus closure, which does not support individualized indomethacin dosing based on monitoring to a target plasma concentration.

AB - A population pharmacokinetic model was developed after administration of orogastric and/or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants. Plasma indomethacin concentrations (n = 227) were obtained from 90 preterm infants of median gestational age 27 weeks, mean postnatal age of 12 days, and a mean current weight (WT) of 1010 g. Infants received one to three courses of indomethacin (0.1 mg/kg per day for 6 days). A one-compartment model was fitted to the data to obtain estimates of clearance (CL), volume of distribution (V), absorption rate constant (Ka) and orogastric bioavailability (F), using NONMEM. Model robustness was assessed by bootstrapping with replacement (500 samples). The structural model was: CL (L/h) = 0.0166 (WT ÷ 0.936); V (L) = 0.484 (WT ÷ 0.936); F = 0.986; Ka (h) = 0.786. The interindividual variability for CL and V was 57.7% and 45.6%, respectively. There remained considerable residual unexplained variability (45.4%). Mean (range) conditional estimates from individual infants for CL, V, and elimination half-life were 18.9 (4.7-45.5) mL/h/kg, 509 (191-1120) mL/kg, and 20.0 (12.0-37.3) hours, respectively. Complete ductus closure occurred in 67% of patients. Infants of lower gestational age or birth weight had less chance of successful ductal closure. There was no obvious dose-response relationship between systemic exposure to varying plasma indomethacin concentrations and ductus closure, which does not support individualized indomethacin dosing based on monitoring to a target plasma concentration.

KW - Ductus arteriosus

KW - Indomethacin

KW - Population pharmacokinetics

KW - Preterm infants

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=36549078271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549078271&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31815b3e13

DO - 10.1097/FTD.0b013e31815b3e13

M3 - Article

C2 - 18043480

AN - SCOPUS:36549078271

VL - 29

SP - 807

EP - 814

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -